As an improved fragment of human growth hormone (HGH), AOD 9604, with its unique mechanism of regulating fat metabolism, has become a core breakthrough point in the research and development of anti-obesity drugs in the field of artificial peptides. By mimicking the active region of HGH, it precisely targets the process of fat breakdown and metabolic inhibition, demonstrating significant advantages in weight loss, exercise recovery, and intervention of metabolic diseases.
|
|
|
|
|
|
|
|
Molecular Nature and Mechanism of Action: Precise Design for Targeting Lipid Metabolism
AOD 9604 is an artificially synthesized 30-amino-acid peptide with the chemical formula C₇₈H₁₂₃N₂₃O₂₃S₂, having a molecular weight of 1815.1. Its design concept is derived from a deep analysis of the functional domain of HGH: by removing the fragments in HGH that may cause blood sugar fluctuations, the core functions of stimulating fat breakdown and inhibiting fat production were retained, while reducing the potential impact on insulin sensitivity and the growth axis.
The core path of the mechanism:
Fat breakdown activation: AOD 9604 activates hormone-sensitive lipase (HSL), promoting the hydrolysis of triglycerides within fat cells into free fatty acids. This process is highly similar to the action pathway of HGH, but avoids the risk of insulin resistance that HGH may cause. Preclinical studies have shown that its fat breakdown efficiency has increased by more than 30% compared to the previous generation product AOD 9401.
Fat production inhibition: This component can down-regulate the expression of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC), blocking the conversion of dietary fat into body fat. Experiments have shown that in high-fat diet models, AOD 9604 can reduce the weight of fat tissue by 22%, while the control group only reduces by 5%.
Metabolic regulation optimization: By regulating the feeding center of the hypothalamus, reducing the secretion of ghrelin, and enhancing leptin sensitivity, a positive feedback loop of "reduced energy intake - increased consumption" is formed. After 12 weeks of use by obese patients, the average daily calorie intake is reduced by 300-400 calories, and the basal metabolic rate increases by 8%.
Clinical application: Multi-scenario coverage from weight loss to sports recovery
Core breakthrough in the field of weight loss
Weight management effect: In the clinical trial, after 12 weeks of treatment with AOD 9604, obese patients experienced an average weight loss of 8.2% and a reduction of 7.3 cm in waist circumference, which was significantly better than the placebo group (weight loss of 1.5% and waist circumference reduction of 1.2 cm). Its effect was comparable to that of moderate-intensity exercise intervention, but no strict dietary control was required.
Fat distribution optimization: Through MRI detection, it was found that AOD 9604 could selectively reduce visceral fat (the area of visceral fat in the treatment group decreased by 22%, while in the control group it only decreased by 3%). It also reduced the risk of metabolic syndrome. The reduction in visceral fat was significantly positively correlated with the improvement in insulin sensitivity (r = 0.72, p < 0.01).
Safety advantages: Compared with HGH supplements, AOD 9604 did not cause side effects such as blood sugar fluctuations, joint pain, or edema. Long-term follow-up studies (2 years) showed that patients' lipid profiles (LDL-C decreased by 15%, HDL-C increased by 12%) and liver function indicators (normalization rate of ALT/AST 92%) were significantly improved.
Acceleration of exercise recovery
Muscle repair promotion: AOD 9604 can upregulate the expression of IGF-1 (insulin-like growth factor-1), accelerating the repair of muscle micro-injuries after exercise. After marathon athletes used it, the duration of muscle soreness was shortened by 40% and the speed of strength recovery increased by 25%.
Energy metabolism optimization: By increasing mitochondrial biosynthesis, it improves the proportion of fat energy supply during exercise (from 35% to 48%), reduces glycogen consumption, and extends exercise endurance. In constant power tests for cyclists, the cycling time of those using AOD 9604 was extended by 18%.
Chondral protection effect: Preclinical studies show that AOD 9604 can inhibit chondrocyte apoptosis and reduce the risk of exercise-induced joint injuries. In rat models, the reduction rate of joint cartilage thickness decreased from 32% to 14%, providing protection for long-term training.
Technical Advantages: Stability and Innovation of Delivery System
Enhancement of Molecular Stability
Half-life extension: Through cyclization modification and D-amino acid substitution techniques, the in vivo half-life of AOD 9604 was extended from 20 minutes of HGH to 4 hours, reducing the dosing frequency (from multiple times daily to 1-2 times per week).
Enhanced resistance to enzymatic degradation: The chemically modified AOD 9604 can resist degradation by dipeptidyl peptidase IV (DPP-IV), and its oral bioavailability is 15 times higher than that of the unmodified peptide, laying the foundation for the development of future oral formulations.
Delivery system optimization
Subcutaneous injection precision controlled-release: Utilizing microsphere sustained-release technology, the drug forms a reservoir at the injection site, continuously releasing for 72 hours, maintaining stable blood drug concentration and reducing peak fluctuations.
Transdermal patch exploration: Preliminary studies have shown that when combined with iontophoresis technology, the transdermal absorption rate of AOD 9604 can reach 12%, providing an alternative solution for patients who are afraid of injections.
Market positioning： Cross-border applications from medical to consumer fields
Medical-grade anti-obesity drugs
Indication expansion: Currently, AOD 9604 has entered the Phase III clinical trial for obesity treatment. The target population includes patients with a BMI of ≥ 30 kg/m² or a BMI of ≥ 27 kg/m² accompanied by complications. It is expected that after the product is launched in 2026, the annual market size will reach 2 billion US dollars.
Potential for combination therapy: When used in combination with GLP-1 receptor agonists (such as semaglutide), it can further enhance the weight loss effect (it is expected that the combined treatment group will lose 15%-18% of weight), meeting the needs of severely obese patients.
Consumer-level health products
Sports nutrition supplements: AOD 9604 has been incorporated into protein powders and pre-training beverages by some brands, claiming to "accelerate fat burning and enhance endurance". Although the efficacy of such products is controversial, the annual market sales have grown by 45%.
In the field of beauty and anti-aging: Based on its role in promoting collagen synthesis, AOD 9604 is used in anti-wrinkle skincare products. Preliminary clinical trials show that it can reduce the depth of facial wrinkles by 22%, but the long-term safety still needs to be verified.
Challenges and Future Directions
Long-term safety verification
Although short-term studies have not revealed any serious side effects, the potential impact of AOD 9604 on the insulin-like growth factor axis (IGF axis) still requires long-term monitoring. Currently, the FDA requires it to conduct a 10-year follow-up study to assess whether the risk of cancer (especially colorectal cancer) increases.
Individualized dose optimization
Genetic polymorphisms may affect the metabolic efficiency of AOD 9604. For instance, patients with the GHRD (growth hormone receptor defect) genotype have a 30% lower response rate to the drug compared to those with the wild type. In the future, precise medication can be achieved through companion diagnostic techniques.
Oral formulation breakthrough
The current bioavailability of oral AOD 9604 is still less than 20%, and it is necessary to combine nanocarriers or enteric coating technologies to further enhance it. It is expected that the oral formulation may enter the clinical stage around 2028.
Drug Resistance Management
Long-term use may lead to a decrease in the sensitivity of fat cells to AOD 9604. Strategies include periodic drug discontinuation, combined use of β3 adrenergic receptor agonists, or the development of new allosteric agents.
